Jasuja Guneet K, Bhasin Shalender, Rose Adam J, Reisman Joel I, Hanlon Joseph T, Miller Donald R, Morreale Anthony P, Pogach Leonard M, Cunningham Francesca E, Park Angela, Wiener Renda S, Gifford Allen L, Berlowitz Dan R
Center for Healthcare Organization and Implementation Research (CHOIR), ENRM VAMC, Bedford, Massachusetts 01730.
Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts 02118.
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3226-3233. doi: 10.1210/jc.2017-00468.
Testosterone prescribing rates have increased substantially in the past decade. However, little is known about the context within which such prescriptions occur.
We evaluated provider- and site-level determinants of receipt of testosterone and of guideline-concordant testosterone prescribing.
This study was cross-sectional in design.
This study was conducted at the Veterans Health Administration (VA).
Study participants were a national cohort of male patients who had received at least one outpatient prescription within the VA during fiscal year (FY) 2008 to FY 2012. A total of 38,648 providers and 130 stations were associated with these patients.
This study measured receipt of testosterone and guideline-concordant testosterone prescribing.
Providers ranging in age from 31 to 60 years, with less experience in the VA [all adjusted odds ratio (AOR), <2; P < 0.01] and credentialed as medical doctors in endocrinology (AOR, 3.88; P < 0.01) and urology (AOR, 1.48; P < 0.01) were more likely to prescribe testosterone compared with older providers, providers of longer VA tenure, and primary care providers, respectively. Sites located in the West compared with the Northeast [AOR, 1.75; 95% confidence interval (CI), 1.45-2.11] and care received at a community-based outpatient clinic compared with a medical center (AOR, 1.22; 95% CI, 1.20-1.24) also predicted testosterone use. Although they were more likely to prescribe testosterone, endocrinologists were also more likely to obtain an appropriate workup before prescribing compared with primary care providers (AOR, 2.14; 95% CI, 1.54-2.97).
Our results highlight the opportunity to intervene at both the provider and the site levels to improve testosterone prescribing. This study also provides a useful example of how to examine contributions to prescribing variation at different levels of the health care system.
在过去十年中,睾酮处方率大幅上升。然而,对于此类处方开具的背景情况知之甚少。
我们评估了睾酮处方开具及符合指南的睾酮处方开具在提供者和机构层面的决定因素。
本研究采用横断面设计。
本研究在退伍军人健康管理局(VA)开展。
研究参与者是一个全国性队列的男性患者,他们在2008财年至2012财年期间在VA接受了至少一张门诊处方。共有38648名提供者和130个机构与这些患者相关。
本研究衡量了睾酮处方开具及符合指南的睾酮处方开具情况。
年龄在31至60岁之间、在VA经验较少(所有校正比值比[AOR],<2;P<0.01)且具有内分泌学(AOR,3.88;P<0.01)和泌尿外科(AOR,1.48;P<0.01)医生资质的提供者,与年龄较大的提供者、在VA任职时间较长的提供者以及初级保健提供者相比,分别更有可能开具睾酮处方。与东北部相比,位于西部的机构(AOR,1.75;95%置信区间[CI],1.45 - 2.11)以及在社区门诊诊所接受的治疗与在医疗中心接受的治疗相比(AOR,1.22;95%CI,1.20 - 1.24)也预示着睾酮的使用。虽然内分泌学家更有可能开具睾酮处方,但与初级保健提供者相比,他们在开处方前也更有可能进行适当的检查(AOR,2.14;95%CI,1.54 - 2.97)。
我们的结果凸显了在提供者和机构层面进行干预以改善睾酮处方开具的机会。本研究还提供了一个有用的示例,说明如何审视医疗保健系统不同层面处方差异的影响因素。